Skip to main content
SpringerLink
Log in

AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Interaction of advanced glycation end products (AGEs) with its cell-bound receptor (RAGE) results in cell dysfunction through activation of nuclear factor kappa-B, increase in expression and release of inflammatory cytokines, and generation of oxygen radicals. Circulating soluble receptors, soluble receptor (sRAGE), endogenous secretory receptor (esRAGE) and cleaved receptor (cRGAE) act as decoy for RAGE ligands and thus have cytoprotective effects. Low levels of sRAGE and esRAGE have been proposed as biomarkers for many diseases. However sRAGE and esRAGE levels are elevated in diabetes and chronic renal diseases and still tissue injury occurs. It is possible that increases in levels of AGEs are greater than increases in the levels of soluble receptors in these two diseases. Some new parameters have to be used which could be an universal biomarkers for cell dysfunction. It is hypothesized that increases in serum levels of AGEs are greater than the increases in the soluble receptors, and that the levels of AGEs is correlated with soluble receptors and that the ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE are elevated in patients with end-stage renal disease (ESRD) and would serve as an universal risk marker for ESRD. The study subject comprised of 88 patients with ESRD and 20 healthy controls. AGEs, sRAGE and esRAGE were measured using commercially available enzyme linked immune assay kits. cRAGE was calculated by subtracting esRAGE from sRAGE. The data show that the serum levels of AGEs, sRAGE, cRAGE are elevated and that the elevation of AGEs was greater than those of soluble receptors. The ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE were elevated and the elevation was similar in AGEs/sRAGE and AGEs/cRAGE but greater than AGEs/esRAGE. The sensitivity, specificity, accuracy, and positive and negative predictive value of AGEs/sRAGE and AGEs/cRAGE were 86.36 and 84.88 %, 86.36 and 80.95 %, 0.98 and 0.905, 96.2 and 94.8 %, and 61.29 and 56.67 % respectively. There was a positive correlation of sRAGE with esRAGE and cRAGE, and AGEs with esRAGE; and negative correlation between sRAGE and AGEs/sRAGE, esRAGE and AGES/esRAGE, and cRAGE and AGES/cRAGE. In conclusion, AGEs/sRAGE, AGEs/cRAGE and AGEs/esRAGE may serve as universal risk biomarkers for ESRD and that AGEs/sRAGE and AGEs/cRAGE are better risk biomarkers than AGEs/esRAGE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Thorpe SR, Baynes JW (2003) Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25(3–4):275–281

    Article  CAS  PubMed  Google Scholar 

  2. Bierhaus A, Hoffmann MA, Ziegler R, Nawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardivasc Res 37(3):586–600

    Article  CAS  Google Scholar 

  3. Tam XHL, Shiu SWM, Leng L, Bucala R, Betteridge DJ, Tan KCB (2011) Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptors in type 2 diabetes. Clin Sci 120:81–89

    Article  CAS  PubMed  Google Scholar 

  4. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H (2003) Novel splice variants of the receptor for advanced glycation end products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Koyama H, Shoji T, Yokoyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25(12):2587–2593

    Article  CAS  PubMed  Google Scholar 

  6. Prasad K (2006) Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 15:57–68

    CAS  Google Scholar 

  7. Schmidt AM, Yan SD, Stern DM (2000) The biology of receptor for advanced glycation end products and its ligands. Biochem Biophys Acta 1498:99–111

    Article  CAS  PubMed  Google Scholar 

  8. Schmidt AM, Yan SD, Wautier JL, Stern DM (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84:489–497

    Article  CAS  PubMed  Google Scholar 

  9. Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25(5):1032–1037

    Article  CAS  PubMed  Google Scholar 

  10. Lindsey JB, de Lemos JA, Cipollone F et al (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32(7):1218–1220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. McNair ED, Wells CR, Qureshi AM et al (2009) Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 18(4):187–192

    Article  PubMed  PubMed Central  Google Scholar 

  12. Santilli F, Bucciarelli L, Noto D et al (2007) Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43(9):1255–1262

    Article  CAS  PubMed  Google Scholar 

  13. Geroldi D, Falcone C, Emanuele E et al (2005) Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23(9):1725–1729

    Article  CAS  PubMed  Google Scholar 

  14. Emanuele E, D’Angelo A, Tomaino C et al (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62(11):1734–1736

    Article  PubMed  Google Scholar 

  15. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW (2011) Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 37(3):516–522

    Article  CAS  PubMed  Google Scholar 

  16. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL (2005) Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 51(9):1749–1750

    Article  CAS  PubMed  Google Scholar 

  17. Nin JW, Jorsal A, Ferreira I et al (2010) Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 59(8):2027–2032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fujisawa K, Katakami N, Kaneto H et al (2013) Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 227(2):425–428

    Article  CAS  PubMed  Google Scholar 

  19. Kalousová M, Hodková M, Kazderová M et al (2006) Soluble receptfor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47(3):406–411

    Article  PubMed  Google Scholar 

  20. Basta G, Leonardis D, Mallamaci F et al (2010) Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 77(3):225–231

    Article  CAS  PubMed  Google Scholar 

  21. Nin JWM, Ferreira I, Schalkwijk CG et al (2009) EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB prospective complications study. Diabetologia 52(4):705–714

    Article  CAS  PubMed  Google Scholar 

  22. Hammady MMR, Khashali SEL, Halim HA, Rashed L, Hussein M (2012) Soluble receptfor for advanced glycation end products (sRAGE) in non-diabetic hemodialysis patients and chronic kidney disease. Med J Cairo Univ 80:69–75

    Google Scholar 

  23. Taki K, Takayama F, Tsuruta Y, Niwa T (2006) Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 70(1):218–224

    Article  CAS  PubMed  Google Scholar 

  24. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22(9):1543–1548

    Article  CAS  PubMed  Google Scholar 

  25. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H (2000) The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 49(8):1030–1035

    Article  CAS  PubMed  Google Scholar 

  26. Raj DS, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a Nephrologist’s perspective. Am J Kidney Dis 35(3):365–380

    Article  CAS  PubMed  Google Scholar 

  27. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP (1994) Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46(1):216–222

    Article  CAS  PubMed  Google Scholar 

  28. Prasad K (2014) Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease states: myth or reality. Int J Angiol 23:11–16

    Article  PubMed  PubMed Central  Google Scholar 

  29. Schmidt AM, Stern D (2000) Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2:430–436

    Article  CAS  PubMed  Google Scholar 

  30. Dalal M, Semba RD, Sun K et al (2011) Endogenous secretory receptor for advanced glycation end products and chronic kidney disease in the elderly population. Am J Nephrol 33:313–318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Vlassara H, Striker LJ, Teichberg S et al (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704–11707

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yamagishi S, Adachi H, Nakamura K et al (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55:1227–1231

    Article  CAS  PubMed  Google Scholar 

  33. Santilli F, Vazzana N, Bucciarelli LG et al (2009) Soluble forms of RAGE in human disease: clinical and therapeutic implications. Curr Med Chem 16:940–952

    Article  CAS  PubMed  Google Scholar 

  34. Caspar-Bell, Dhar I, Prasad K (2016) Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism. Mol Cell Biochem 414(1):171–178

    Article  CAS  PubMed  Google Scholar 

  35. Ubarri J, Kai W, Pebba M, Goodman S, Ferruci L, Striker G, Vlassara H (2007) Circulating glycotoxins and dietary advanced glycation end products: two links to inflammatory response, oxidative stress, and aging. J Gerantol Ser A 62:427–433

    Article  Google Scholar 

  36. McNair E, Qureshi M, Prasad K, Pearce C (2016) Atherosclerosis and hypercholesterolemic AGE-RAGE axis. Int J Angiol 25:110–116

    Article  PubMed  Google Scholar 

  37. Mook-Kanamori MJ, Ed-Din Selim MM, Takiddin AH, Al-Homsi H, Al-Mahmond KAS, Al-Obaid A, Zine MA, Row J, Gherbi WS, Chidiac OM, Kador SA, Al-Muftah WAA, McKean C, Suhre K, Mook-Kanamori DO (2013) Ethnic and gender differences in advanced glycation end products measured by skin auto-fluorescence. Dermatoendocrinol 5:325–330

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We acknowledge the help of Dr. H. Lim, Director of Clinical Research Support Unit of the Department of Community Health and Epidemiology, for statistical analysis.

Author information

Authors and Affiliations

  1. Department of Physiology, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada

    Kailash Prasad, Indu Dhar & Muhammad Shoker

  2. Department of Medicine, College of Medicine and Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada

    Qifeng Zhou, Hamdi Elmoselhi & Ahmed Shoker

Authors
  1. Kailash Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Indu Dhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qifeng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hamdi Elmoselhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammad Shoker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmed Shoker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kailash Prasad.

Ethics declarations

Conflicts of interest

The results presented in this paper have not been published previously in whole or part, even in the abstract format. There is no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prasad, K., Dhar, I., Zhou, Q. et al. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem 423, 105–114 (2016). https://doi.org/10.1007/s11010-016-2829-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-016-2829-4

Keywords

Search

Navigation